CD19 and diffuse large B-cell lymphoma: At the end of 2021, another anti-CD19 CAR-T cell, Breyanzi® (lisocabtagene maraleucel) from Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (Seattle, Washington), was granted authorization for the treatment of adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.